Osimertinib Recruiting Phase 2 Trials for Glioblastomas / TP53 wt Allele / Supratentorial Glioblastoma / EGFR Gene Amplification / Recurrent Glioblastoma / EGFR Gene Mutations Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT0373235218F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma